Request Demo
Last update 28 Jan 2026
HB002.1T
Last update 28 Jan 2026
Overview
Basic Info
Drug Type Fc fusion protein |
Synonyms HB 002T, HB-002, HB-002.1T + [3] |
Target |
Action inhibitors, antagonists |
Mechanism TGFBR2 inhibitors(Transforming growth factor beta receptor 2 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with HB002.1TCTR20200664
HB002.1T注射液治疗晚期实体瘤患者的安全性，耐受性及药代动力学的I期临床试验
[Translation] Phase I clinical trial of the safety, tolerability and pharmacokinetics of HB002.1T injection in patients with advanced solid tumors
NCT04802980
A Phase Ib, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety, Tolerability and Pharmacokinetics of HB002.1T in Combination With Chemotherapy in Patients With Advanced Solid Tumors.
NCT03636750
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravenous Injections of HB002.1T (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Solid Tumor
100 Clinical Results associated with HB002.1T
Login to view more data
100 Translational Medicine associated with HB002.1T
Login to view more data
100 Patents (Medical) associated with HB002.1T
Login to view more data
100 Deals associated with HB002.1T
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 2 | China | 17 Nov 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 28 Apr 2020 | |
| Advanced cancer | Phase 1 | China | 20 Sep 2018 |
Login to view more data
Clinical Result
Clinical Result
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free